Published in Magn Reson Imaging on July 06, 2012
Estimating dose painting effects in radiotherapy: a mathematical model. PLoS One (2014) 0.90
Review of treatment assessment using DCE-MRI in breast cancer radiation therapy. World J Methodol (2014) 0.86
A unifying probabilistic Bayesian approach to derive electron density from MRI for radiation therapy treatment planning. Phys Med Biol (2014) 0.81
Treatment assessment of radiotherapy using MR functional quantitative imaging. World J Radiol (2015) 0.78
Functional imaging for radiotherapy treatment planning: current status and future directions-a review. Br J Radiol (2015) 0.77
Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study. Radiat Oncol (2015) 0.75
Commissioning of a new wide-bore MRI scanner for radiotherapy planning of head and neck cancer. Br J Radiol (2013) 0.75
Multimodality functional imaging using DW-MRI and (18)F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience. World J Radiol (2017) 0.75
Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors. Radiat Oncol (2016) 0.75
Evaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison study. Phys Med Biol (2016) 0.75
Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. Technol Cancer Res Treat (2016) 0.75
Focal therapy for prostate cancer: the technical challenges. J Contemp Brachytherapy (2017) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Correction for geometric distortion in echo planar images from B0 field variations. Magn Reson Med (1995) 7.71
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys (2000) 4.99
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol (2005) 4.68
Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med (2005) 3.26
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol (2005) 2.65
A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging (2007) 2.32
Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging. Radiology (2011) 2.18
Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging (2006) 1.94
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
MRI/linac integration. Radiother Oncol (2007) 1.81
A technique for accurate magnetic resonance imaging in the presence of field inhomogeneities. IEEE Trans Med Imaging (1992) 1.80
Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol (2009) 1.63
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.51
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol (2011) 1.49
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol (2010) 1.40
Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol (2011) 1.38
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36
Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys (1996) 1.36
Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. Radiother Oncol (2008) 1.35
A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging (2008) 1.32
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys (2007) 1.31
Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience. Radiology (2004) 1.29
Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys (2002) 1.24
Image-guided radiotherapy: has it influenced patient outcomes? Semin Radiat Oncol (2012) 1.23
Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging (2010) 1.21
Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys (2008) 1.20
Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging (2004) 1.18
Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol (2010) 1.15
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys (2008) 1.14
Adapting radiotherapy to hypoxic tumours. Phys Med Biol (2006) 1.14
Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys (2005) 1.12
Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol (2010) 1.11
Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys (2011) 1.09
Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.08
Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys (2011) 1.07
Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. Med Phys (2010) 1.05
PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging (2010) 1.04
On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol (2009) 1.04
A complete distortion correction for MR images: II. Rectification of static-field inhomogeneities by similarity-based profile mapping. Phys Med Biol (2005) 1.04
Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol (2010) 1.03
Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys (2008) 1.02
Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol (2012) 1.02
Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol (2007) 1.01
Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. Magn Reson Imaging (2007) 1.01
MR susceptibility misregistration correction. IEEE Trans Med Imaging (1993) 0.99
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A (2011) 0.98
Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging (2010) 0.98
Image guided, adaptive, accelerated, high dose brachytherapy as model for advanced small volume radiotherapy. Radiother Oncol (2011) 0.98
Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol (2005) 0.96
Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol (1999) 0.95
Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys (2011) 0.93
Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol (2009) 0.92
Clinical evaluation of stereotactic target localization using 3-Tesla MRI for radiosurgery planning. Int J Radiat Oncol Biol Phys (2009) 0.91
Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol (2010) 0.88
Magnetic resonance imaging protocol optimization for delineation of gross tumor volume in hypopharyngeal and laryngeal tumors. Int J Radiat Oncol Biol Phys (2009) 0.87
Development of a geometrically accurate imaging protocol at 3 Tesla MRI for stereotactic radiosurgery treatment planning. Phys Med Biol (2010) 0.86
Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer. Radiother Oncol (2011) 0.86
Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy. Magn Reson Imaging (2010) 0.86
Analysis of machine-dependent and object-induced geometric distortion in 2DFT MR imaging. Magn Reson Imaging (1992) 0.85
Hearing preservation in vestibular schwannoma stereotactic radiosurgery: what really matters? J Neurosurg (2008) 0.85
Analysis and correction of geometric distortions in 1.5 T magnetic resonance images for use in radiotherapy treatment planning. Phys Med Biol (1995) 0.85
Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys (2011) 0.85
Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. Int J Radiat Oncol Biol Phys (2010) 0.85
Planning in the IGRT context: closing the loop. Semin Radiat Oncol (2007) 0.84
Supine breast MRI. J Magn Reson Imaging (2011) 0.83
Feasibility of MRI guided proton therapy: magnetic field dose effects. Phys Med Biol (2008) 0.82
Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiother Oncol (2009) 0.81
FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiother Oncol (2011) 0.79
Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability. Radiology (2010) 0.76
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol (2010) 5.65
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol (2011) 3.43
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Tailoring the atomic structure of graphene nanoribbons by scanning tunnelling microscope lithography. Nat Nanotechnol (2008) 2.49
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol (2009) 2.21
Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging. Radiology (2011) 2.18
Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol (2013) 2.11
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med (2008) 2.08
Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology (2005) 1.94
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (2007) 1.76
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol (2012) 1.68
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys (2010) 1.66
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol (2004) 1.61
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol (2008) 1.53
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol (2008) 1.51
Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2006) 1.51
Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet (2006) 1.50
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol (2011) 1.49
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol (2010) 1.44
Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol (2011) 1.38
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev (2006) 1.35
Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2006) 1.34
Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol (2007) 1.34
Liver volumetry plug and play: do it yourself with ImageJ. World J Surg (2007) 1.34
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology (2013) 1.31
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2005) 1.24
Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys (2003) 1.24
Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys (2010) 1.23
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.22
The Currarino triad: neurosurgical considerations. Neurosurgery (2006) 1.22
The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol (2005) 1.22
A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 1.22
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med (2012) 1.21
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys (2005) 1.18
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol (2004) 1.17
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys (2009) 1.15
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol (2010) 1.15
Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg (2011) 1.15
A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg (2009) 1.14
USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology (2008) 1.14
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer (2005) 1.14
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys (2004) 1.13
Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging (2012) 1.13
Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiother Oncol (2007) 1.13
Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology (2008) 1.12
Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall? Radiology (2009) 1.12
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev (2007) 1.12
Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed (2006) 1.11
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol (2007) 1.11
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med (2012) 1.10
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol (2009) 1.09
Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer-a per lesion validation study. Eur Radiol (2010) 1.08
The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev (2010) 1.08
Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol (2009) 1.08
Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys (2008) 1.08
Targeting hypoxia tolerance in cancer. Drug Resist Updat (2004) 1.07
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful? Radiology (2004) 1.07
Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys (2008) 1.07
Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology (2009) 1.06
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol (2006) 1.06
Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol (2008) 1.06
Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy. Med Phys (2009) 1.05
A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One (2011) 1.05
Health-related quality of life in patients surviving non-small cell lung cancer. Thorax (2010) 1.05
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol (2012) 1.05
Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol (2007) 1.05
PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging (2010) 1.04
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem (2009) 1.04
Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer. BMC Cancer (2010) 1.04
Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol Ther (2006) 1.03
Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem (2009) 1.03
Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol (2002) 1.03
Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol (2003) 1.02
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol (2009) 1.02
When to wait for more evidence? Real options analysis in proton therapy. Oncologist (2011) 1.02
Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol (2010) 1.02
Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol (2013) 1.02
Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol (2005) 1.01
Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiother Oncol (2013) 1.01
Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol (2010) 1.01
Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol (2007) 1.00
Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.00